news

Inovio’s INO-3112 DNA immunotherapy shows positive preliminary results

Posted: 9 April 2015 |

INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)…

Inovio Pharmaceuticals has announced preliminary data showing that its INO-3112 DNA immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.

dna-immunotherapy

INO-3112, an active immunotherapy that targets HPV 16 and 18 and simultaneously expresses IL-12, is designed to activate in vivo (in the body) immune responses to antigens from high risk HPV types and eliminate precancerous and cancerous cells displaying these antigens. The data, which are T cell measurements from the first four treated patients of this Phase I/IIa study, are being presented at the World Vaccine Congress 2015 by Inovio’s COO, Dr. Niranjan Y. Sardesai. 

This is the first study of T cell immune responses after treatment with an Inovio DNA immunotherapy

These positive results represent the first study and first report of T cell immune responses generated in cancer patients after treatment with an Inovio DNA immunotherapy. The magnitude and characteristics of these interim immune response data mirror immune responses previously observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “This initial data set from Inovio’s first cancer study provides encouraging evidence that we are on an important path to better optimized immunotherapy products. Regardless of whether it is an infectious disease, a precancer, or a cancer: the immune system uses the same mechanism to eliminate infected or mutated cells. In immune-oncology, it’s all about the T cells. Here we show in cancer patients that we can generate antigen-specific CD8+ killer T cell responses, which are essential to an effective immunotherapy.

“We look forward to completing our currently enrolling studies for HPV-associated head & neck and cervical cancers, completing the preparations for our planned phase III study for cervical precancer, and launching new studies for hepatitis B and prostate cancer that all rely on the same targeted T-cell-based killing activity.”

This open label study of HPV-caused head and neck cancer is intended to assess the safety, tolerability, and immunogenicity of INO-3112 in up to twenty adults with HPV-positive head and neck squamous cell carcinoma.

For more information about Inovio’s INO-3112 DNA immunotherapy, please visit www.inovio.com.